- Shares of Galena Biopharma (GALE +3.9%) are enjoying a strong session.
- SA contributor and long-time bull Regarded Solutions is out reiterating a positive outlook for the company going into the new year.
- "GALE should continue to deliver positive results as they proceed in Phase 3 trials of [their] potential legacy drug, NeuVax," the author says, adding that "sales of Abstral could surprise everyone."
From other sites
at Zacks.com (Mar 18, 2015)
at Zacks.com (Mar 9, 2015)
at CNBC.com (May 21, 2014)
at CNBC.com (Apr 8, 2014)
at CNBC.com (Mar 17, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs